Canakinumab Anti-inflammatory Thrombosis Outcome Study (CANTOS), a large clinical trial utilizing anti-inflammatory treatment with Canakinumab, a monoclonal antibody targeting IL-1β, demonstrated that inhibition of IL-1β expression decreased recurrent cardiovascular events, thus preventing coronary heart disease. Here, IL1B is linked to coronary artery disorder.